Page 3 - Strides Pharma

Strides Pharma posts Rs 43 cr Q4 profit vs Rs 207 cr loss a year ago

Company to launch generic products to aid Covid-19 treatment in India, first being Liposomal Amphotericin B to treat black fungus

Stock picks by Sameet Chavan: Buy Strides Pharma, sell Grasim

We finally witnessed a decisive price and volume breakout from the recent congestion zone in Strides Pharma

Stelis Biopharma raises $195 mn for vaccination unit, contract business

Vaccine unit will manufacture up to 800 million doses of vaccines annually

India's Stelis Biopharma to make 200 mn doses of Sputnik V vaccine

India has now become one of the biggest producers of Sputnik V outside of Russia. Other countries that are producing it include South Korea, Brazil and China

Strides Pharma to spin off biopharma biz, start vaccines with global player

Entity Stelis Biopharma to require up to $100-mn additional funds in 3 years

Former HDFC Bank Managing Director Aditya Puri joins Strides Group

Former HDFC Bank managing director Aditya Puri has joined global pharma major Strides Group as an advisor and will also serve as a director of its associate company Stelis Biopharma.

Strides Pharma to set up 800-mn capacity vaccine suite in Bengaluru

In talks with global players seeking manufacturing opportunity for potential Covid-19 vaccine

Strides Pharma Science arm gets USFDA nod for Ethacrynic Acid tablets

Drug firm Strides Pharma Science on Tuesday said its step down subsidiary has received approval from the US health regulator for Ethacrynic Acid tablets, used to treat fluid retention (edema)

Strides Pharma hits a fresh 52-week high; stock gains 14% in one week

The company had reported a strong improvement in profitability in Q1 despite Ranitidine suspension in Q4.

Strides Pharma extends rally; soars 64% in two months; hits 52-week high

The company reported strong performance across all businesses in Q1FY21 despite significant disruptions and ambiguity in the business environment due to Covid 19.

Strides Pharma gets US FDA nod for generic anti-inflammatory drug

Drug firm Strides Pharma Science on Thursday said it has received approval from the US health regulator for generic Prednisone tablets used as an anti-inflammatory medication. Strides Pharma Global Pte Ltd, Singapore, company's step-down wholly owned subsidiary, has received approval for Prednisone tablets USP in the strength of 1 mg from the United States Food & Drug Administration (USFDA), Strides Pharma Science said in a filing to the BSE. The product is a generic version of Schering Corporation's Meticorten tablets in the same strength, it added. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market,the filing said. According to IQVIA MAT July 2020 data, the US market for Prednisone tablets USP 1 mg is approximately USD 12 million (about Rs 88 crore), it added. Prednisone belongs to a class of drugs known as corticosteroids and is used as an anti-inflammatory or an immunosuppressant medication. It i

Strides Pharma shares zoom 8% on US FDA approval for Ursodiol tablets

Ursodiol is used for treatment of patients with primary biliary cirrhosis (PBC)

We are looking at vaccines as new growth pivot: Strides Pharma chief

In a Q&A, pharma major's MD & CEO, R Ananthanarayanan says the firm is setting up a vaccine suite and is in final-stage talks with global players to seal a deal for developing a Covid-19 vaccine

Strides Pharma gets DGCI approval to test potential Covid-19 drug

Glenmark was the first Indian firm to get approval from regulator to conduct trials on Favipiravir tablets, which are otherwise used to treat influenza

Strides Pharma to conduct trials for potential Covid-19 drug Favipiravir

Favipiravir is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014

Drug to treat Covid-19 ready, says Strides Pharma; stock rises 20%

Firm says will apply to Indian pharma authorities to start studies

Strides Pharma posts threefold rise in profit-before-tax at Rs 103.6 crore

The Bengaluru-headquartered company posted a 358 per cent rise in net profit at 101 crore as compared to the corresponding quarter of the previous financial year

Strides Pharma likely to launch affordable insulin from Stelis stable

The Bengaluru-headquartered company believes Stelis could be a disruptor in insulin accessibility and affordability.

Ranitidine cancer threat: Expect more clarity on products in coming weeks

Ranitidine sales account for 2 per cent of Strides sales and 6 per cent of its profit after tax

Strides Pharma posts Rs 140 crore profit before tax for September quarter

It had posted a loss of Rs 8.70 crore for the corresponding period of FY19.